Teva Pharmaceutical Industries (TEVA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic transformation and growth focus

• Achieved seven consecutive quarters of revenue growth, transforming from a debt-burdened generics company to a global biopharmaceutical leader with a strong innovative pipeline.

• Four-pillar strategy: invest in growth engines (Austedo, Uzedy, Ajovy), step up innovation, sustain generics powerhouse, and disciplined capital allocation.

• Transparent goal-setting and accountability have driven rapid execution and exceeded initial targets, especially in innovative product launches and pipeline acceleration.

• Divestiture of Teva API and Japan BV remains on schedule for H1 2025, supporting business focus and capital allocation for growth.

• Debt reduction efforts have improved credit ratings, with net debt/EBITDA reduced to 3.04x and positive outlooks from major agencies.

Product and pipeline highlights

• Austedo family revenue outlook raised to $1.6B for 2024, targeting $2.5B by 2027; Uzedy expected to surpass $100M in first-year sales; Ajovy continues steady growth, expected at $500M in 2024.

• Duvakitug (anti-TL1A) showed best-in-class phase 2 data in UC and Crohn's, with phase 3 starting in 2025 and potential for multiple indications.

• Olanzapine LAI program met primary endpoint in schizophrenia, aiming for 2026 launch; ICS/SABA (Daria) pediatric-friendly inhaler in phase 3, expected in 2027.

• Biosimilars portfolio expanded to 18 assets, with 5-6 launches planned in the next two years, targeting >$60B originator value.

• Generics business returned to growth in the US, providing strong cash generation and ongoing productivity initiatives to offset price erosion.

Financial outlook and capital allocation

• Committed to mid-single-digit revenue growth, 30% operating profit, net debt/EBITDA of 2x, and 80%+ cash conversion by 2027.

• Non-GAAP operating margin improved to 27.1% YTD Q3 2024, with free cash flow conversion at 81.7%.

• Continued debt reduction, reinvestment in growth drivers, and disciplined business development focused on synergistic, low-risk opportunities.

• 2025 priorities: drive innovative product growth, accelerate pipeline (olanzapine, ICS/SABA, duvakitug), divest TAPI, and maintain generics momentum.

• Austedo's exposure to Part D redesign is minimal in 2025; planning for potential IRA impact in 2027.